DOI: 10.1007/s13311-017-0557-4 Pages: 1-7
Article Type: Review

Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis

1. University of California, Multiple Sclerosis Center, Weill Institute for Neurosciences

Correspondence to:
Stephen L. Hauser
Email: stephen.hauser@ucsf.edu

Close

Abstract

Selective depletion of CD20+ B cells by anti-CD20 monoclonal antibodies as monotherapy in multiple sclerosis (MS) profoundly suppresses acute inflammatory disease activity and signifies an important advance in the treatment of relapsing-remitting MS. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, is also the first proven therapy to lessen disability progression in primary progressive MS—a breakthrough for patients with a disease that had no proven therapy. Ocrelizumab is generally well tolerated, with the most common adverse events experienced being infusion reactions and infections. In ocrelizumab trials in MS a numerical imbalance in the risk of malignancies was observed. In this article, we review advances in anti-CD20 B-cell-depleting biological therapies for MS, including ocrelizumab, rituximab, and ofatumumab.

To access the full text, please Sign in

If you have institutional access, please click here

  • Online: Jul 10, 2017

Article Tools